Sep 18, 2022 / 01:00PM GMT
Lauren Tengler - Boston Scientific Corporation - Director of IR
Welcome, everyone, both here in the room and on the webcast today. We're excited to welcome our cardiology leadership team, but before we get to that, I'm going to go through some housekeeping items. First, we'll be providing forward-looking statements, so typical safe harbor and risk factors apply. Second, here are some of our regulatory and financial disclaimers. And with that, I'd like to hand it over to Joe Fitzgerald, Executive Vice President and President of Cardiology Group.
Joseph M. Fitzgerald - Boston Scientific Corporation - Executive VP & Group President of Cardiology
Well, that was quicker than I thought, but thank you, Lauren. Good morning, everybody. Thanks for joining us. We have the majority of our cardiology leadership team here with [Lance], who runs our coronary and structural components; Jim Cassidy runs our WATCHMAN franchise; and then the well-known Dr. Ian Meredith, who covers everything in cardiology. So again, thanks for joining.
I want to just give a
Boston Scientific Corp Investor Update at TCT Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers